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1,2
Clinically, AM has been used as an allograft across multiple disciplines. Particularly in ophthalmology, transplantation of AM has become a standard surgical procedure for ocular surface reconstruction to promote epithelialisation and reduce inflammation and scarring. 3 Elsewhere, cryopreserved amniotic tissue has been used to treat wounds in different types of tissue including tendon 4,5 and nerve repair. 6,7 AM was used to cover open wounds as early as 1910, 8 and has also been used on wounds caused by many other aetiologies such as venous leg ulcers, 9-12 pressure ulcers 9, [13] [14] [15] , diabetes mellitus, 15 trauma 15,16 and burns.
17-22
While the clinical use of AM is well documented, the use of umbilical cord (UC) tissue in this setting is relatively new. Comprised of AM with additional components unique to the foetal environment, it is likely that UC would have comparable, if not increased, effectiveness to AM in both biological and functional assays and is therefore included in the analyses presented here.
The successful commercialisation of any tissue product relies on the effective preservation of key biological components essential to maintaining the intended therapeutic action of the tissue. Differences in processing methods can dramatically alter both the structural and biochemical composition of the tissue, and impair the activity of vital signalling molecules such as cytokines, proteoglycans and growth factors, which are critical to the intended use of the product. 23 From AM, we have successfully purified and characterised 'HC-HA/PTX3' as a unique matrix component responsible for its therapeutic actions.
24-28,30 HC-HA/PTX3 is formed by tight association between pentraxin 3 (PTX3), a member of the pentraxin family of proteins, known to be involved in innate immunity, and HC-HA, a high molecular weight (HMW) hyaluronic acid (HA) covalently linked to heavy chain 1 (HC1) of inter-α-trypsin inhibitor (IαI). [24] [25] [26] [27] [28] 30 In vitro, soluble HC-HA/PTX3 suppresses the proliferation and promotes apoptosis of lipopolysaccharide (LPS)-induced macrophages. 27 Additionally, immobilised HC-HA/PTX3 upregulates IL-10 and downregulates IL-12 upon stimulation of IFN-α and LPS to polarise macrophages toward the M2 (activated macrophage) phenotype which plays an integral role in promoting the healing response.
27-29 Therefore, measurement of the presence and function of HC-HA/PTX3 can be used to judge how well different processing methods may preserve the therapeutic actions of AM and UC.
While several processing methods exist, the most widely employed are cryopreservation and dehydration via heat drying. In order to judge the effects of cryopreservation on AM and UC tissues, we recently reported that cryopreserved AM/UC is comparable to fresh AM/UC based on the retention of key architectural and biochemical components essential for the therapeutic actions of the tissues. 31 Here, we extend our study to compare cryopreserved AM/UC tissues with dehydrated amnion/chorion tissues in order to verify whether different processing methods might affect tissue integrity and therapeutic potential.
Materials and methods

Tissue preparation
Cryopreserved human AM (CT-AM) and UC (CT-UC) tissue processed by the CryoTek (CT) method (US 6,326,019, US 6,152,142 and PCT/ US2010/046675) was provided by TissueTech, Inc. (Miami, FL) and compared with dehydrated tissue (dHACM), processed by the PURION method (US 8,323,701).To prepare cryopreserved AM and UC tissues, donated full-term human placentas with the umbilical cord were recovered after cesarean-section delivery in compliance with American Association of Tissue Banks (AATB) standards and immediately stored at -80°C for up to one year. Prior to processing, the frozen placenta and UC were thawed at room temperature for 8 hours in a Good Manufacturing Practice (GMP) facility before being placed at 8°C for an additional 16 hours. Under aseptic conditions, the placenta and UC were first cleaned of blood clots with phaosphate-buffered saline (PBS) prior to separation of AM and UC by blunt dissection. The chorion was separated from AM and blood vessels were stripped from UC to generate a flat graft before gentle rinsing in PBS until all blood coloration was removed. AM was affixed on a filter membrane and cut to 6 x 6cm while UC was cut to 6 x 3cm. The AM or UC tissue was finally packaged in a pouch containing 1:1 v/v Dulbecco Modified Eagle Medium (DMEM) and glycerol before storage at -80°C for up to two years.
Histology and histochemistry
Cryopreserved tissues were allowed to thaw for 10 minutes at room temperature and dehydrated samples were rehydrated according to package instructions. All tissues were fixed with 10% formalin for one hour, washed three times with PBS for five minutes each, and cut with a 15mm biopsy punch to obtain equal-sized tissue samples. Tissues were subsequently embedded in histogel, processed, embedded into paraffin blocks, and cut into 5μm sections. Histological sections were then stained with either hematoxylin & eosin (H&E), Masson's trichrome (MAS), or Safranin O (SafO) with Fast Green FCF counterstain. For HA histochemistry, de-paraffinised sections were incubated with biotinylated Hyaluronic Acid Binding Protein (HABP) followed by Alexa Fluor 488 streptavidin. Nuclei were counterstained with Hoechst-33342 and images were photographed by laser confocal microscopy (LSM700, Axio Observer.Z1, Zeiss, Germany).
Tissue-extract preparation
The preparation of tissue extracts for CT-AM, CT-UC and dHACM was carried out aseptically as previously reported. 32 To assess the retention of key biochemical molecules, homogenised tissues were extracted by 4M guanidine hydrochloride and the supernatant dialysed against PBS for 30 hours to obtain water-soluble extracts from each tissue. Protein content was quantified using a standard BCA assay (Pierce) while quantification of HA was performed by HABP-coated microwell kit (Corgenix).
determination of Ha sizes by agarose-gel electrophoresis
The molecular weight of HA in tissue extracts was analysed by agarose gel electrophoresis as previously reported. 33 Tissue extracts were loaded at the same equivalent (15µg) of HA per lane with or without pretreatment (one hour, 37°C) with 9 units HAase per μg. The samples were separated on a 0.5% agarose gel at 20V for the first 30 minutes and then 40V for 4 hours. The gel was subsequently stained with 0.005% Stains-all dye in 50% ethanol overnight at 25°C in the dark before destaining in water and exposing to ambient light for 6 hours. The molecular weight range of HA samples, which appear as a
western blot
Tissue-extract samples were loaded with equivalent (20µg) protein per lane with or without pretreatment (one hour, 37°C) with two units of HAase per μg HA before denaturation in Laemmli Buffer (1:1 dilution with sample) at 95°C for five minutes. Samples were then electrophoresed and electrophoretically transferred on to a 0.45µm nitrocellulose membrane. The membrane was then blocked with 5% fat-free milk in tris-buffered saline and tween 20 (TBST) and sequentially incubated with mouse antihuman primary antibodies against HC1 (1:1000) in 5% fat-free milk in TBST (16 hours, 4°C) followed by rabbit anti-mouse HRP-conjugated secondary antibody (1:1000) in 5% fat-free milk in TBST (two hours, room temperature). Immunoreactive protein bands were detected with Western Lightning Chemiluminesence Reagent and imaged by a Luminescent Image Analyzer (ImageQuant LAS 4000, GE). The same membrane was rinsed and stripped with Restore Plus Western Blot Stripping Buffer and then re-blocked with 5% fat-free milk in TBST and sequentially incubated with rat anti-human primary antibodies against PTX3 (1:1000) in 5% fat-free milk in TBST (16 hours, 4°C) followed by goat antirat HRP-conjugated secondary antibody (1:1000) in 5% fat-free milk in TBST (2 hours, room temperature). Immunoreactive protein bands were detected with Western Lighting Chemiluminesence Reagent and imaged by a Luminescent Image Analyzer.
Macrophage proliferation assay
RAW264.7 cells were seeded at a density of 156 cells/ mm 2 on a 96-well plate in DMEM/10% foetal bovine serum (FBS) (t=0) and treated at t=2 hours with either CT-AM, CT-UC, or dHACM tissue extracts containing 100μg protein/ml, or PBS vehicle control before activation with IFN-α (200units/ml) and LPS (1μg/ml) at t=3 hours. At t=25 hours, cells were labelled with 10µM BrdU for 2 hours and were subsequently fixed with FixDenat (provided in BrdU ELISA kit, Roche) at 25°C for 30 minutes, followed by incubation with anti-BrdU-peroxidase conjugate at 25°C for 2 hours. The colour was developed for 30 minutes by adding the substrate tetramethylbenzidine (TMB) and stopped by adding 1M H 2 SO 4 . Colorimetric measurements were performed at 450nm with a reference wavelength at 690nm.
Macrophage cell death assay
RAW264.7 cells were seeded and treated as above for the first three hours. At t=27 hours, cell lysates were collected using lysis buffer (provided in Cell Death ELISA kit, Roche). The cell lysate (20μl) was transferred to a microplate and 80μl of Immunoreagent was added before incubation at 300rpm (2 hours, 25°C). After incubation, wells were rinsed three times with 300μl incubation buffer. The colour was developed for 20 min by adding 100μl of ABTS solution and stopped by adding 100μl ABTS Stop Solution. Colorimetric measurements were performed at 405nm with a reference.
elISa analysis
RAW264.7 cells were seeded at a density of 250 cells/ mm 2 on a 24-well plate in DMEM/10% FBS (t=0) and treated at t=2 hours with either CT-AM, CT-UC, or dHACM tissue extracts containing 100μg protein/ml, or PBS vehicle control before activation with IFN-α (200 units/ml) and LPS (1μg/ml) at t=3 hours. Culture media from each well was collected at t=27 hours for IL-10 and IL-12 ELISA analysis. Briefly, a capture antibody was adsorbed onto a 96-well plate, followed by a blocking step, incubation with 100µL sample, and binding of analyte to a biotinylated detection antibody. Concentrations of capture and detection antibodies were used according to the manufacturer's protocol (BioLegend). IL-10 or IL-12 in the cell supernatants was assessed using the colorimetric reaction of peroxidase TMB at an absorbance reading of 450nm.
Statistical analysis
Unless otherwise indicated, data are represented as mean±standard error with a sample size of three or more for each condition. A Student's t-test was performed to test for statistical significance in protein levels with Microsoft Office Excel 2007. An analysis of variance (ANOVA) coupled with Tukey's post-hoc analysis was performed to test statistical significance for HA quantification, macrophage cell proliferation, macrophage cell death and ELISA analysis with SPSS Statistics 20 (IBM). Where p<0.05 the results were considered statistically significant.
Results
Histological and immunohistochemical staining
To compare the effects of cryopreservation and dehydration on tissue morphology and extracellular matrix (ECM) components, sections were examined by histochemical staining We have previously shown that cryopreserved AM/UC tissues contain no significant structural differences compared with fresh tissues. 31 As seen previously, H&E staining revealed that the structural morphology of CT-AM (Fig 1a) closely resembled that of fresh AM tissue, which contains a thin basement membrane sandwiched between a simple epithelium and an avascular stroma. As expected, CT-UC mirrored this morphology, with an expanded stromal layer (Fig 1b) . In contrast, dHACM contained a layer of chorion in addition to the AM layer, and was dramatically compacted in comparison to the cryopreserved tissue (Fig 1c) . Both Masson's Trichrome (Fig 1 d-f ) and Safranin O staining (Fig 1 g-i) , used to indicate ECM collagen content and sulfated proteoglycans, respectively, corroborated these results. Collectively, these findings support the notion that cryopreservation did not cause notable changes in the histological properties of thin or thick AM tissue, while dehydration drastically altered the structural integrity of the tissue.
Biochemical analyses of Ha and Hc-Ha
Recent studies have indicated HC-HA/PTX3 is a key signalling proteoglycan present in AM/UC. [25] [26] [27] [28] 30, 31 Histochemistry with HABP was performed to visualise the density and distribution of HA within the ECM of cryopreserved AM/UC and dHACM. HA staining was positive in the AM stroma but absent in the amniotic epithelium for all tissues. Of note, HA was only weakly present in the subjacent chorion of dHACM. Cryopreserved tissues presented robust uniform staining across the stromal layer, especially apparent in the thick stromal layer of the CT-UC (Figs 2 a and b,) . dHACM exhibited only modest HA staining that was sporadically distributed throughout the ECM, indicating the disruption and removal of HA originally present in the membrane by this processing method (Fig 2c) . The absence of staining following pretreatment of histologic sections with HAase confirmed the specificity of HA staining (Fig. 2 d-f) .
To directly quantify the differences in ECM HA content, tissue extracts were analysed using an HABP assay. While both cryopreserved samples exhibited an increased HA/total protein ratio compared to dHACM, the results only reached significance in the CT-UC sample (Fig 3) . Consistent with HA staining, the CT-UC sample contained significantly more (~50X) HA than dHACM. Of note, while not significantly different, CT-AM contained three times more HA than the dehydrated tissue, likely due to the chorion layer contributing to an increase in total protein while appearing to have comparatively little HA.
The molecular weight of HA has been tied to different biological outcomes in vivo with critical distinction between low molecular weight HA (LMW HA) and high molecular weight (HMW) HA. 33 To determine the size distribution of HA in the tissue extracts, we used agarose gel electrophoresis followed by Stains-all dye as previously described.
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Staining was shown to be specific for HA by the disappearance of the HMW HA fraction with HAase digestion (Fig 4, lanes 6-8) . HA from CT-UC (Fig 4,  lane 4) Healon control (Fig 4, lane 2) in the range of 1000 to 6000 kDa, indicating that UC preferentially contained HMW HA. In contrast, dHACM contained no HMW HA, instead displaying a LMW HA smear at the bottom of the gel (Fig 4, lane 5) with a molecular weight below 500 kDa. Interestingly, a HMW band was detected in the loading wells of both CT-AM and CT-UC samples (Fig 4, lanes 3 and 4) which was abolished after HAase digestion (Fig 4, lanes 6 and 7) , suggesting the presence of a HMW HA species in cryopreserved AM/UC that was larger than that of Healon. In contrast, no band from the dehydrated sample existed in the loading well (Fig 4, lane 5) , corroborating the LMW smear within the lane. Previous research has shown that the HA present in AM/UC exists as a HC-HA/PTX3 complex.
25-28,30,31
To determine if this complex was altered or destroyed by the dehydration processing method, we subjected tissue extracts from cryopreserved and dehydrated tissues to Western blot using an HC1-specific antibody. Additionally, to ensure that HC1 was indeed associated with HA, tissue-extract samples were examined in parallel by first treating one replicate with NaOH, which hydrolyses the ester bond between HA and HC1. As expected, IαI purified from human plasma yielded a major band at ~250kDa (Fig 5, lane 2) and treatment of IαI with 50mM NaOH cleaved the ester bonds linking the HCs to IαI to yield a 75kDa HC1 fragment (Fig 5,  lane 3) . As seen in the agarose gel, both cryopreserved tissues contained a band that remained in the well (Fig 5, lanes 5 and 7) most likely HC-HA, because digestion with NaOH partially cleaved the complex to yield an increase in the intensity of the 75kDa HC1 fragment (Fig. 5, lanes 6 and 8) indicating that the HC-HA complex is present in both CT-AM and CT-UC tissues. Interestingly, a band remained in the CT-UC well even after digestion with NaOH, possibly due to the large amount of HA within the CT-UC extract. The dehydrated sample did not contain any HMW bands and exhibited the 75kDa HC1 band before and after digestion, suggesting the lack of the HC-HA complex due to the degradation and removal of HMW HA, leaving only unbound LMW HA.
PTX3 content
PTX3 is an oligomeric protein shown to be constitutively expressed in the AM that serves to stabilise the HC-HA complex. 30, 34 In order to determine the effects of processing methods on PTX3 protein levels, tissue extracts were analysed via Western blot. PTX3 exists as two forms: a ~45kDa monomer and ~90kDa dimer (Fig 6, lane 4) . Cryopreserved tissue extracts had strong PTX3 bands at 45 and 90kDa (Fig 6, lanes 5-8) . In addition, the CT-UC sample contained another band that remained in the well due to its large size (Fig 6, lanes 7 and 8) , similar to AM's anti-inflammatory activity has been demonstrated by the suppression of viability and proliferation of macrophages by both AM tissue 35, 36 and AM extracts.
3,32 To explore the effect of processing on innate activity, tissue extracts containing 100µg protein/ml from either cryopreserved or dehydrated samples were applied to activated RAW264.7 cells, (a macrophage cell line) and both macrophage proliferation (Fig 7a) and cell death (Fig 7b) were measured in separate assays. Compared with cells in the PBS vehicle control, RAW264.7 macrophages treated with cryopreserved tissue extracts showed significantly inhibited proliferation (p<0.01; ANOVA followed by Turkey's post-hoc test). However, tissue extract from dehydrated samples was comparable to the control and displayed no significant effect. Furthermore, only CT-UC was significantly (p<0.01; ANOVA followed by Turkey's post-hoc test) more effective than the control in promoting macrophage apoptosis. In fact, CT-UC-stimulated apoptosis was approximately 14 times more greater than that seen with all other tissue extracts.
elISa quantification of cytokines
We have previously reported that the HC-HA/PTX3 complex downregulates pro-inflammatory cytokines while upregulating anti-inflammatory cytokines. 27, 28, 30 ELISA analysis of two critical cytokines IL-10 (anti-inflammatory) and IL-12 (proinflammatory) was performed to elucidate what effects, if any, processing techniques had on HC-HA/PTX3 ability to regulate cytokine expression. CT-UC extract dramatically increased IL-10 expression compared to all other samples, with IL-10 levels approximately 8-fold higher than dehydrated samples (Fig 8a) . When assessing IL-12 expression, all samples were significantly different to control, with CT-AM and dHACM exhibiting similar expression levels and CT-UC reducing IL-12 expression 7-fold more than dHACM (Fig 8b) .
Discussion
Fresh AM has been proven efficacious in clinical applications.
11,37,38 However, its use presents a serious risk of disease transmission. 39, 40 Therefore, processing methods that ensure the safety of the tissue while preserving its innate biological effectiveness become critical. With several processing protocols commonly used, techniques differ dramatically and can have varying impacts on both the structural and biochemical composition of the tissue, as well as the activity of critical signalling molecules (cytokines, proteoglycans, etc), essential to the therapeutic actions of the tissue. 23 Specific to the methods compared here, the cryopreservation process involves quickly freezing the tissue and was specifically developed to maintain the structural integrity of the extracellular matrix and the endogenous biochemical functions of the native AM and UC tissues. In contrast, dehydration is much harsher and has been shown to cause protein denaturation, loss of function, and irreparable damage to the ultrastructure and material properties of the tissue, resulting in loss of cell attachment and decreased cell infiltration. 23, [41] [42] [43] This process creates the potential for compromising the survival and permanence of key anti-inflammatory and anti-scarring factors, suggesting the clinical efficacy of tissue processed by this method may be lessened.
Histological analysis revealed that the ECM architectural structure within CT-AM and CT-UC was not altered by cryopreservation but was compromised by dehydration. This is a critical finding, as the proteins within the ECM regulate the functions of cells and small molecules, and act as a reservoir and modulator of cytokines and growth factors. 44, 45 Moreover, the healing potential of AM is mediated by the complex assembly of these components, [46] [47] [48] further indicating the importance of maintaining the integrity of the ECM after preservation. Of note, cryopreserved tissues were comparable in structure to fresh AM 31 while dehydrated tissues were notably impaired, indicated by the compact appearance of the stromal and chorion layers.
The clinical success of AM/UC as a potent antiinflammatory and anti-scarring agent has prompted examination into the physiological mechanism of its therapeutic actions. Previous studies revealed AM's regenerative potential may be mediated by complex arrays of cytokines, chemokines, and growth factors which have been linked to the promotion of wound healing via suppression of host immune cells. 49, 50 Recent studies have implicated HA complex as a critical biological component that contributes to the anti-inflammatory and anti-scarring properties of AM. 25, 28, 30, 32 Cryopreservation retained high levels of HA within both CT-AM and CT-UC samples and also preserved the distribution of HA across the stromal layer of the tissues. In contrast, while HA was still present in the dHACM sample, the distribution was radically altered, with sporadic pockets of HA randomly dispersed throughout the tissue and total levels of HA much lower, comparatively. Moreover, the HA present within cryopreserved tissues, particularly CT-UC, was HMW HA, while the HA contained in dHACM was LMW HA. This is of particular interest because certain studies have suggested HMW HA is the key isoform of HA responsible for the therapeutic properties mentioned above while LMW HA contributes to the inflammatory response and is immune-stimulatory. We have previously shown that HMW HA in AM exists within the HC-HA complex that is stabilised by the multimeric protein PTX3 25, 26, 28, 30 and that this larger complex exerts a more powerful therapeutic effect than HMW HA alone.
27,28 Western blot analyses clearly showed the presence of this crucial matrix component in both CT-AM and CT-UC samples, further supporting that the cryopreservation process does not disturb the innate biological components of the ECM with AM tissue. On the contrary, the dHACM sample contained neither HC-HA nor PTX3, only displaying LMW HA and HC1 fragments. While the presence of these smaller proteins may impart some transient beneficial effects to the dHACM, the lack of the key ECM components HC-HA and PTX3 suggests reduced longevity of the active components within the tissue, following the dehydration process.
While macrophage activation during inflammation is critical to the body's response to insult, persistence at the site of injury can result in chronic inflammation and inability to heal properly, often leading to tissue damage. [52] [53] [54] Recent studies have shown the unique ability of HC-HA/PTX3 to promote the death of activated macrophages while downregulating proinflammatory cytokines and upregulating antiinflammatory cytokines. 25, 27, 28, 30 The results here demonstrate the ability of CT-AM and CT-UC to significantly reduce activated macrophage proliferation and the substantial ability of CT-UC to enhance activated macrophage apoptosis when compared to dHACM. Due to the aforementioned retention of high levels of HC-HA and PTX3 within the cryopreserved tissues, the ability of CT-AM and CT-UC to modulate macrophage cell survival and growth is not surprising, and is imperative to their success in wound healing. Similarly, the lack of HC-HA and PTX3 within dHACM may contribute to the decreased effectiveness of the dehydrated tissue in reducing inflammation and fibrosis in vivo. 55 Additionally, cytokines are known to play critical roles in wound healing.
56,57 IL-10 and IL-12 are well studied cytokines and are known to be anti-and pro-inflammatory, respectively.
58-60 Similar to results seen with pure HC-HA/PTX3, 27,28,30 CT-UC significantly increased IL-10 expression while decreasing IL-12 expression, most likely due to the substantially higher levels of HC-HA within CT-UC tissue compared to AM alone.
While the data presented here adequately tests and describes the differences in structure, function, and biochemical make-up of both cryopreserved and dehydrated tissues, the study does have its limitations. Only a single cryopreservation and dehydration processing method were analysed and future experiments including tissues processed by varying cryopreservation and dehydration protocols should be performed to see if the differences outlined here extend to other tissues with similar processing techniques. Additionally, while the IL-10/IL-12 ratio is indicative of M1 to M2 macrophage polarisation, an additional experiments should include analysis of a larger panel of cytokines to more fully understand the immunomodulatory actions of the tissue. Finally, to truly understand the efficacy of the tissue, in vivo experiments should be performed in various models of inflammation and disease.
conclusion
Overall, the results of this comparative study bring to light considerable differences in the structural and biochemical properties of cryopreserved and dehydrated foetal tissues. Histological analysis revealed that while cryopreservation did not damage the delicate architecture of the ECM with the tissue, dehydration resulted in a compacted AM morphology and altered the distribution of structural matrix components. Furthermore, the key molecules of HC-HA and PTX3 were absent in the dehydrated tissue and only LMW HA and HC1 proteins were identified, most likely byproducts of ECM compaction and alteration after preservation. Not surprisingly, the lack of these critical molecules lessened the biological activity of the dHACM, as evidenced in the functional assays. Cryopreserved tissues retained elevated levels of crucial biological elements and exhibited high functionality in modulating macrophage viability and cytokine expression. Taken together, this data strongly suggests that cryopreservation effectively preserves the structural and biochemical integrity of AM and UC matrix components, essential for the anti-inflammatory and anti-scarring effects observed clinically. n
